trending Market Intelligence /marketintelligence/en/news-insights/trending/whktjim2kno1bi0_xvmsgw2 content esgSubNav
In This List

Histogenics receives Nasdaq noncompliance notice

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Histogenics receives Nasdaq noncompliance notice

Histogenics Corp. received a notice from Nasdaq for failing to meet the exchange's $1 minimum bid price listing requirement.

The Waltham, Mass.-based biotechnology company has until April 15, 2019, to regain compliance for continued listing on the Nasdaq Capital Market.

If the company fails to regain compliance by then, it may be delisted from the stock exchange.

Histogenics is a clinical-stage company that develops restorative cell therapies in the U.S.